Anti-Jk^a Antibody: Definition and Clinical Implications
What is Anti-Jk^a?
Anti-Jk^a is an alloantibody directed against the Jk^a antigen of the Kidd blood group system, notorious for causing delayed hemolytic transfusion reactions (DHTRs) and being difficult to detect due to its transient nature and tendency to fall below detectable levels between transfusions. 1
Key Clinical Implications
Transfusion Reactions
- Anti-Jk^a is a highly clinically significant antibody that frequently causes delayed hemolytic transfusion reactions, typically occurring 6-10 days post-transfusion with symptoms including weakness, fatigue, nausea, jaundice, and dropping hemoglobin levels 2
- The antibody can cause both acute and delayed hemolytic reactions, with documented cases showing hemolysis even when the antibody was initially undetectable by standard gel testing methods 1
- In one study of 32 patients where anti-Jk^a was detected by solid-phase testing but missed by gel testing, 17 were recently transfused: 6 developed confirmed DHTRs, 3 had possible DHTRs, and 8 had delayed serologic reactions 1
Detection Challenges
- Anti-Jk^a antibodies are heterogeneous and notoriously difficult to detect because they can become undetectable between transfusion episodes, making them a common cause of unexpected hemolytic reactions 2
- Solid-phase red blood cell adherence (SPRCA) testing detects anti-Jk^a more reliably than gel column agglutination, identifying clinically significant antibodies that gel methods completely miss 1
- The antibody demonstrates dosage phenomenon (reacts more strongly with homozygous Jk(a+a+) cells than heterozygous Jk(a+b+) cells) 2
Hemolytic Disease of the Fetus and Newborn (HDFN)
- Anti-Jk^a can cause HDFN, though this is rare, with documented cases showing total serum bilirubin levels reaching 20.5 mg/dL on day 3 of life requiring phototherapy 3
- The antibody is of IgG type and can cross the placenta, potentially causing severe HDFN and persistent anemia in infants 3
Transplant-Related Complications
- Passenger lymphocyte syndrome can occur in solid organ transplantation, where donor lymphocytes produce anti-Jk^a against the recipient's Jk(a+) red cells, causing clinically significant hemolysis weeks after transplantation 4
Prevention and Management Strategy
Prophylactic Antigen Matching
The American Society of Hematology strongly recommends prophylactic red cell antigen matching for extended antigens including Jk^a/Jk^b (along with Rh C, E, K, Fy^a/Fy^b, and S/s) over ABO/RhD matching alone to prevent alloimmunization. 5
- Extended antigen matching reduces the alloimmunization incidence rate from 1.94 per 100 units (ABO/RhD matching alone) to 0.25 per 100 units (extended matching) 5
- This matching strategy prevents subsequent acute and delayed HTRs, difficulty identifying antigen-negative units, and transfusion delays 5
Extended Red Cell Antigen Profiling
All patients should receive an extended red cell antigen profile (including Jk^a/Jk^b) by genotype or serology at the earliest opportunity, optimally before the first transfusion. 5
- Genotyping is preferred over serologic phenotyping as it provides more comprehensive antigen information and increased accuracy 5
- The extended profile should include at minimum: C/c, E/e, K, Jk^a/Jk^b, Fy^a/Fy^b, M/N, and S/s 5
- Document the patient's Kidd phenotype in the medical record for future transfusion planning 6
Critical Monitoring
- Keep pretransfusion samples for three weeks to allow retrospective antibody identification if DHTR occurs 2
- Monitor clinical effect of transfusion regularly, particularly days 6-10 post-transfusion when DHTRs typically manifest 2
- Maintain high index of suspicion for DHTR in any patient with unexplained hemoglobin drop, jaundice, or elevated bilirubin after transfusion 2